drugset / Trial / NCT02365532

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

NCT02365532

Phase 1 Completed 60 enrolled Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.

Timeline

Start
2015-02
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eleclazine Small molecule Oral
Background Dofetilide Small molecule 500 ug Oral

Indications